Paxman Inkomsten in het verleden

Verleden criteriumcontroles 3/6

Paxman has been growing earnings at an average annual rate of 32.4%, while the Medical Equipment industry saw earnings growing at 21.2% annually. Revenues have been growing at an average rate of 24.2% per year. Paxman's return on equity is 19.6%, and it has net margins of 11.5%.

Belangrijke informatie

32.4%

Groei van de winst

31.6%

Groei van de winst per aandeel

Medical Equipment Groei van de industrie6.2%
Inkomstengroei24.2%
Rendement op eigen vermogen19.6%
Nettomarge11.5%
Volgende winstupdate15 Nov 2024

Recente prestatie-updates uit het verleden

Recent updates

Is It Time To Consider Buying Paxman AB (publ) (STO:PAX)?

Oct 22
Is It Time To Consider Buying Paxman AB (publ) (STO:PAX)?

Results: Paxman AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts

Aug 24
Results: Paxman AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts

Paxman (STO:PAX) Might Have The Makings Of A Multi-Bagger

Aug 07
Paxman (STO:PAX) Might Have The Makings Of A Multi-Bagger

After Leaping 28% Paxman AB (publ) (STO:PAX) Shares Are Not Flying Under The Radar

Jul 18
After Leaping 28% Paxman AB (publ) (STO:PAX) Shares Are Not Flying Under The Radar

Even With A 29% Surge, Cautious Investors Are Not Rewarding Paxman AB (publ)'s (STO:PAX) Performance Completely

May 24
Even With A 29% Surge, Cautious Investors Are Not Rewarding Paxman AB (publ)'s (STO:PAX) Performance Completely

Does Paxman (STO:PAX) Have A Healthy Balance Sheet?

Dec 23
Does Paxman (STO:PAX) Have A Healthy Balance Sheet?

Paxman (STO:PAX) Shareholders Will Want The ROCE Trajectory To Continue

Aug 25
Paxman (STO:PAX) Shareholders Will Want The ROCE Trajectory To Continue

Paxman AB (publ) (STO:PAX) Could Be Riskier Than It Looks

Jun 01
Paxman AB (publ) (STO:PAX) Could Be Riskier Than It Looks

Does Paxman (STO:PAX) Have A Healthy Balance Sheet?

Nov 20
Does Paxman (STO:PAX) Have A Healthy Balance Sheet?

Is Paxman (STO:PAX) A Risky Investment?

Mar 07
Is Paxman (STO:PAX) A Risky Investment?

Paxman (STO:PAX) Is Making Moderate Use Of Debt

Mar 15
Paxman (STO:PAX) Is Making Moderate Use Of Debt

Are Insiders Buying Paxman AB (publ) (STO:PAX) Stock?

Jan 22
Are Insiders Buying Paxman AB (publ) (STO:PAX) Stock?

Reflecting on Paxman's (STO:PAX) Share Price Returns Over The Last Year

Dec 18
Reflecting on Paxman's (STO:PAX) Share Price Returns Over The Last Year

Opbrengsten en kosten

Hoe Paxman geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

OM:PAX Opbrengsten, kosten en inkomsten (SEK Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 2424829640
31 Mar 2423624610
31 Dec 232218590
30 Sep 232081940
30 Jun 23188-2550
31 Mar 23173-7530
31 Dec 22157-10490
30 Sep 22143-2730
30 Jun 22125-12700
31 Mar 22111-18650
31 Dec 21105-13620
30 Sep 2193-23610
30 Jun 2187-21570
31 Mar 2180-22540
31 Dec 2083-19540
30 Sep 2090-6560
30 Jun 2096-1560
31 Mar 201026580
31 Dec 19963570
30 Sep 1990-4500
30 Jun 1983-5490
31 Mar 1975-6470
31 Dec 1869-7460
30 Sep 1858-9370
30 Jun 1850-10350
31 Mar 1843-9330
31 Dec 1736-7310

Kwaliteitswinsten: PAX has high quality earnings.

Groeiende winstmarge: PAX became profitable in the past.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: PAX has become profitable over the past 5 years, growing earnings by 32.4% per year.

Versnelling van de groei: PAX has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Winst versus industrie: PAX has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Rendement op eigen vermogen

Hoge ROE: PAX's Return on Equity (19.6%) is considered low.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden